Aquestive Therapeutics (NASDAQ:AQST) stock is falling on Wednesday after the pharmaceutical company revealed details of a public offering for its shares.
Aquestive Therapeutics is selling 16,666,667 shares of AQST stock for $4.50 each in this public offering. There’s also a 30-day option for underwriters to acquire an additional 2.5 million shares at that same price.
Aquestive Therapeutics is expecting $75 million in gross proceeds from the stock offering. The company will use these funds to continue the development and commercialization of its product pipeline.
Aquestive Therapeutics has several products in development. That includes Anaphylm Sublingual Film for severe life-threatening allergic reactions and Libervant Buccal Film for seizure clusters in epilepsy patients. The funds will also be used for general corporate purposes.
How This Affects AQST Stock
This public offering increases the total number of outstanding shares of AQST stock. That dilutes current shareholder’s stakes in the company. This is one reason why the shares are down today.
Another is the price of shares in the offering. The $4.50 offering price is a significant discount from the prior closing price of $5.34 per share. It makes sense the stock’s price would drop to closer match the offering price as a result.
AQST stock is down 14% as of Wednesday morning. However, shares were up 165.7% year-to-date when markets closed yesterday.
Investors seeking out even more of the most recent stock market stories are in luck!
We have all of the hottest stock market news ready to go on Wednesday! That includes everything happening with shares of Harrow (NASDAQ:HROW), Chewy (NYSE:CHWY) and Oblong (NASDAQ:OBLG) stock today. All of that news is available at the links below!
More Stock Market News for Wednesday
- Why Is Harrow (HROW) Stock Up 5% Today?
- Trade of the Day: Chew on Chewy (CHWY) Call Options
- Why Is Oblong (OBLG) Stock Up 83% Today?
On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.
